WebThe trial aims to reduce major adverse cardiovascular events (MACE). The dal-GenE trial is fully recruited, passed a futility analysis in January 2024, and trial completion is expected … WebDalCor is set to increase enrolment in its ongoing dal-GenE trial, a Phase III clinical study of dalcetrapib, from 5000 to 6000 patients. The development is based on better than expected enrolment results witnessed by dal-GenE, which has so far randomised a total of 4300 patients around five months ahead of enrolment projections.

DalCor Pharmaceuticals Therillia

WebJan 17, 2024 · Dal-GenE was a double-blind, parallel-group, placebo-controlled, randomized trial comparing orally administered dalcetrapib 600 mg once daily with placebo in a 1:1 ratio. 12 The randomization was... WebApr 1, 2024 · Study design dal-GenE is a double-blind, parallel group, placebo-controlled randomized trial in patients recently hospitalized for ACS and confirmed to have the AA … india baby care products market

DalCor Announces Expansion and Accelerated Enrollment of the dal-GenE ...

WebJul 27, 2024 · It is currently being evaluated in the dal-GenE Phase 3 cardiovascular clinical outcomes trial aiming to deliver a relative risk reduction of 15% or greater for major … Webdal-gene Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population with a Recent ACS This study is in follow-up. Primary Objective: A placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. WebJul 18, 2024 · However, the functional evolution and origin of the DAL gene family is unknown. In this study, we identified the DAL proteins in various plant lineages, … lm products birmingham